Viatris-owned Mylan is selling its entire 5.64% stake in Biocon Ltd through block deals at a floor price of ₹378.50 per share. The exit follows Biocon's recent strong Q4 FY25 performance, where net profit surged 154%. Investors should note that the sale is priced at a discount to the current market rate, which may influence short-term trading patterns.
Viatris-owned Mylan has initiated a full exit from the Indian biotechnology major Biocon Ltd by offloading its entire 5.64% shareholding through block deals. The transaction is being executed at a floor price of ₹378.50 per share, which represents a discount of approximately 7.9% compared to the prevailing market price. This move marks the conclusion of a significant investment relationship between the two entities, which intensified earlier this year.
Origins of the Shareholding
Mylan’s stake in Biocon was built through a strategic restructuring related to Biocon Biologics. In January 2026, the company finalized a deal involving a share swap and cash, which granted Mylan a preferential allotment of shares in the parent company, Biocon Ltd. This transaction had initially pushed Mylan's ownership in the Indian firm to over 6%. By offloading this remaining stake, Mylan is effectively liquidating the position it gained following the consolidation of its biologics business with Biocon.
Financial Context and Market Performance
The divestment comes shortly after Biocon reported a strong financial showing for the fourth quarter of fiscal year 2025. The company posted a net profit of ₹344.5 crore, marking a 154% increase from ₹135.5 crore in the same period a year earlier. This result surpassed analyst expectations, which had pegged net profit at approximately ₹167.7 crore. Revenue for the quarter also showed growth, rising 12.8% year-on-year to ₹4,417 crore, again beating market forecasts of ₹4,168.6 crore. Furthermore, the company reported an EBITDA of ₹1,078.2 crore, indicating robust operational performance.
Implications for Investors
For shareholders, the primary impact of this development is the supply of a significant volume of shares entering the market via block deals. Because the floor price is set at a discount to the market rate, the stock may face temporary pressure as the market absorbs this block of shares. Historically, large exits by institutional shareholders often lead to short-term price volatility. However, the sell-off is viewed as a strategic capital management decision by Mylan rather than a reflection of Biocon’s current operational health. Investors should monitor how the stock price stabilizes once this large sell-off is completed. The focus for shareholders will now shift toward Biocon's ability to maintain its margin expansion and growth momentum in the upcoming quarters, independent of its partnership structure with Viatris/Mylan.